List of Excipients in Branded Drug GENTAK

Generic Drugs Containing GENTAK

Company	Ingredient	NDC	Excipient
Akorn	gentamicin sulfate	17478-284	METHYLPARABEN
Akorn	gentamicin sulfate	17478-284	MINERAL OIL
Akorn	gentamicin sulfate	17478-284	PETROLATUM
Akorn	gentamicin sulfate	17478-284	PROPYLPARABEN
Akorn	gentamicin sulfate	17478-827	METHYLPARABEN
Akorn	gentamicin sulfate	17478-827	MINERAL OIL

What are the Most Frequently-Used Excipients in GENTAK?

# Of NDCs	Excipient
8	METHYLPARABEN
8	MINERAL OIL
8	PETROLATUM
8	PROPYLPARABEN

Gentak Excipient Strategy and Commercial Opportunities for Tobramycin Ophthalmic Ointment

Last updated: September 5, 2026

Gentak is a sterile ophthalmic ointment containing tobramycin 0.3% w/w. Its labeled inactive ingredients are mineral oil and white petrolatum, which create an anhydrous, preservative-free ophthalmic base.[1] The commercial opportunity is primarily a generic or private-label ophthalmic ointment platform, not a new-molecule exclusivity play. The strongest product differentiation options are improved tolerability, lower visual blurring, easier administration, packaging performance, supply reliability, and combination-product extensions.

What is Gentak and which excipients does it contain?

Gentak is an ophthalmic ointment for topical treatment of external ocular infections caused by susceptible microorganisms. The active ingredient is tobramycin, an aminoglycoside antibiotic. The labeled strength is 0.3% w/w.[1]

Product attribute	Gentak profile
Active ingredient	Tobramycin
Dosage form	Sterile ophthalmic ointment
Strength	0.3% w/w
Route	Ophthalmic
Primary indication	Bacterial infections of the external eye
Labeled excipients	Mineral oil and white petrolatum
Preservative system	No added aqueous preservative
Packaging	Sterile ophthalmic tube
Regulatory pathway for equivalent product	Generally ANDA, subject to FDA product-specific requirements

Mineral oil functions as the liquid hydrocarbon phase. White petrolatum supplies the semisolid structure, occlusive properties, and residence time on the ocular surface. The combination avoids an aqueous vehicle and eliminates the need for benzalkonium chloride or another conventional ophthalmic preservative.

The formulation is technically simple but commercially sensitive. Small changes in hydrocarbon grade, petrolatum consistency, mixing temperature, active-particle size, tube geometry, or filling conditions can affect drug uniformity, extrusion force, ocular residence time, and patient acceptability.

What excipient strategy best matches Gentak?

The lowest-risk strategy is to reproduce the established mineral oil and white petrolatum system using pharmaceutical-grade materials with comparable functional characteristics.

Base composition and functional roles

Excipient	Primary function	Key development variables
Mineral oil	Liquid vehicle and wetting phase	Viscosity, purity, hydrocarbon profile, oxidation control
White petrolatum	Ointment structure and occlusion	Consistency, melting range, particle-free quality, rheology
No added preservative	Microbiological control through anhydrous sterile manufacture and packaging	Sterility assurance, container-closure integrity, in-use handling

A direct-equivalent product should avoid unnecessary excipient additions. Surfactants, antioxidants, penetration enhancers, or viscosity modifiers may create regulatory and clinical comparability issues without providing a clear commercial benefit.

Excipient quality requirements

The development program should control:

• Mineral-oil viscosity and hydrocarbon composition.
• White-petrolatum consistency and melting behavior.
• Peroxide and oxidation levels.
• Visible and subvisible particulate matter.
• Bioburden before sterilizing or aseptic processing.
• Active distribution throughout the ointment.
• Ointment extrusion force at intended storage temperatures.
• Container-closure integrity after filling and shipping.

USP-NF compliance is necessary but may not be sufficient. Two pharmacopeial materials can differ in rheology and ocular performance. The supplier qualification program should therefore include lot-to-lot rheological testing and a change-control agreement.

What formulations are protected by Gentak’s excipient profile?

The core formulation is not meaningfully differentiated by a novel excipient combination. Mineral oil and white petrolatum are established ophthalmic ointment vehicles, and their use is unlikely to support meaningful formulation exclusivity by itself.

A formulation patent would require a technically specific improvement, such as:

• A defined hydrocarbon viscosity range.
• A narrow petrolatum consistency or melting profile.
• A controlled particle-size distribution for tobramycin.
• Improved drug uniformity during storage.
• Reduced grittiness or reduced transient visual blur.
• A defined extrusion-force profile.
• A novel sterile manufacturing process.
• A container-closure system that improves dose delivery or sterility maintenance.

The commercial value of such claims would depend on whether the improvement is clinically relevant, reproducible, and difficult to design around. Broad claims covering mineral oil and petrolatum would face substantial prior-art pressure.

When does Gentak lose exclusivity?

Gentak is an old small-molecule ophthalmic product. Its commercial position is governed primarily by abbreviated drug approval, product listing, manufacturing capability, and market access rather than by remaining new-molecule exclusivity.

Exclusivity category	Commercial assessment
New chemical entity exclusivity	Not relevant to tobramycin ophthalmic ointment
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Pediatric exclusivity	No product-specific benefit should be assumed without current FDA records
Formulation exclusivity	Depends on any separately listed and still-enforceable patent claims
Orange Book patent protection	Must be verified against current FDA Orange Book records
Market protection	Primarily depends on manufacturing, supply, pricing, and ANDA competition

Tobramycin was approved decades ago, and the core active-ingredient patent estate is not expected to prevent ordinary generic competition. A company entering the market should focus on current Orange Book listings, FDA product-specific guidance, reference-listed-drug status, and any litigation involving an approved or proposed product rather than historical tobramycin patents.[2]

What is the Orange Book status of Gentak?

FDA Orange Book status should be assessed using the exact reference-listed-drug entry, dosage form, strength, and applicant name. Ophthalmic ointments are listed separately from tobramycin ophthalmic solutions and combination products.

The key diligence questions are:

1. Is Gentak listed as the reference listed drug for tobramycin ophthalmic ointment?
2. Does the current listing contain any active patent information?
3. Are there approved ANDAs for the same strength and dosage form?
4. Has FDA issued product-specific bioequivalence or pharmaceutical-equivalence recommendations?
5. Is the product currently marketed, discontinued, or subject to a shortage notice?

A generic applicant should not assume that a patent-free active ingredient means an uncomplicated ANDA. FDA may require evidence addressing pharmaceutical equivalence, sterility, content uniformity, ointment performance, and comparative microbiological quality.

Which companies are challenging Gentak or competing with it?

Competition exists across several product categories:

Competitive category	Examples
Tobramycin ophthalmic ointment	Generic equivalents to tobramycin 0.3% ointment
Tobramycin ophthalmic solution	Tobramycin 0.3% solution products
Tobramycin/dexamethasone products	Combination antibiotic-corticosteroid products
Other ophthalmic antibiotics	Erythromycin ointment, bacitracin-polymyxin products, fluoroquinolone drops
Hospital and institutional suppliers	Private-label and contract-manufactured ophthalmic products

The main competitive threat is usually not a patent challenger. It is a supplier with an approved ANDA, reliable sterile ophthalmic capacity, and lower acquisition cost.

The market can support multiple suppliers because ophthalmic ointments are used in retail, ophthalmology, urgent care, pediatrics, hospital discharge, and selected neonatal settings. However, demand is limited compared with ophthalmic solutions, and substitution can occur where prescribers prefer drops because ointments temporarily blur vision.

What generic entry risks exist for Gentak?

Regulatory risk

A generic applicant must demonstrate that its product matches the reference product in dosage form, strength, route, and active ingredient. The formulation should generally use the same inactive ingredients or demonstrate that any difference does not affect safety or performance.

Potential FDA review issues include:

• Inadequate drug-content uniformity.
• Non-equivalent ointment rheology.
• Excessive extrusion force.
• Inconsistent fill weight.
• Particle-size differences.
• Inadequate sterility assurance.
• Container-closure leakage.
• Tube extractables or leachables.
• Insufficient stability data.
• Different labeling or administration instructions.

Manufacturing risk

Ophthalmic ointment manufacturing requires tight control of sterile processing. The anhydrous base does not eliminate microbial risk. Contaminants can survive in hydrocarbon systems, and filling operations can introduce contamination after bulk manufacture.

Critical process controls include:

• Controlled excipient dispensing.
• Validated heating and mixing cycles.
• Deaeration.
• Uniform active incorporation.
• Sterile bulk handling or validated sterilization approach.
• Aseptic tube filling.
• In-process weight control.
• Terminal container-closure testing.

A manufacturer that lacks ophthalmic tube-filling experience may face higher development cost and longer technology-transfer timelines than a conventional topical manufacturer.

How can excipient innovation create commercial opportunities?

The most credible opportunities are incremental products that preserve the basic hydrocarbon platform while improving user experience or supply economics.

Lower-blur ointment

Ocular ointments commonly cause temporary visual blurring. A lower-viscosity or narrower-rheology formulation could improve acceptability, but reducing residence time may undermine therapeutic performance. The development target should balance:

• Lower apparent viscosity.
• Adequate ocular retention.
• Reduced dose variability.
• Acceptable extrusion force.
• No increase in irritation.
• Equivalent antimicrobial exposure.

A successful product could compete on patient convenience rather than price alone.

Improved tube delivery

Tube design is a significant commercial variable. Opportunities include:

• Smaller-dose delivery.
• More consistent ribbon length.
• Reduced residual product in the tube.
• Better cap retention.
• Lower contamination risk during repeated use.
• Unit-dose packaging for institutional settings.

A proprietary nozzle or closure may provide stronger practical differentiation than a new excipient.

Unit-dose or single-use packaging

Single-use packaging can reduce contamination concerns and support hospital, surgical, pediatric, or emergency-care channels. The disadvantages are higher packaging cost, more material use, and potentially lower retail convenience.

Private-label and contract manufacturing

An approved tobramycin ointment platform can support:

• Retail pharmacy private labels.
• Hospital formularies.
• Group purchasing organization contracts.
• Regional distributors.
• International products using country-specific registration pathways.
• Bundled ophthalmic antibiotic portfolios.

The commercial advantage comes from manufacturing utilization and portfolio breadth. A supplier producing tobramycin, erythromycin, polymyxin combinations, and corticosteroid combinations can spread sterile filling and quality costs across multiple products.

How does Gentak compare with tobramycin ophthalmic solution?

Factor	Tobramycin ophthalmic ointment	Tobramycin ophthalmic solution
Vehicle	Mineral oil and white petrolatum	Aqueous vehicle
Preservative need	Typically preservative-free	Often requires preservative unless unit-dose
Ocular residence	Longer	Shorter
Visual effect	Greater temporary blurring	Less blurring
Manufacturing	Sterile ointment filling	Sterile liquid filling
Packaging	Ophthalmic tube	Dropper bottle or unit-dose container
Differentiation	Rheology, delivery, comfort	Drop size, preservative profile, bottle performance
Main patient tradeoff	Retention versus blur	Convenience versus dosing frequency

The ointment format is attractive for nighttime use and cases where longer ocular contact is desired. The solution format is often preferred during daytime treatment. A company with both dosage forms can offer prescribers a complementary product set.

What patent litigation and Paragraph IV risks affect Gentak?

A Paragraph IV certification is relevant only if the current Orange Book entry contains an applicable patent. For an old tobramycin ophthalmic ointment, the principal risk is likely to arise from a later formulation, delivery, or combination-product patent rather than from the basic tobramycin composition.

A generic applicant should review:

• Current Orange Book patent listings.
• FDA patent certifications.
• District court complaints under Hatch-Waxman.
• Any 30-month stay triggered by a Paragraph IV notice.
• Patent-term adjustments and pediatric extensions.
• Settlement agreements restricting launch timing.
• Non-patent regulatory exclusivity.

No commercial launch plan should rely on an assumed patent expiry date without confirming the current FDA listing and the specific claims asserted against the proposed product.[2,3]

What licensing deals could support a Gentak opportunity?

Licensing targets generally fall into four categories:

1. An approved ANDA that requires a new commercial partner.
2. A contract manufacturer with validated sterile ophthalmic ointment capacity.
3. A tube or unit-dose packaging technology.
4. A formulation platform with clinical or regulatory data supporting improved tolerability.

The strongest deal structure is usually a supply-and-commercialization agreement with minimum volume commitments, dual-source rights, defined change-control procedures, and responsibility for FDA supplements. A pure formulation license is less attractive if the formulation does not carry enforceable claims or a clear performance advantage.

What is the revenue exposure and market attractiveness?

Gentak is unlikely to have the revenue profile of a protected branded ophthalmic product. Revenue depends on:

• Number of approved competitors.
• Generic price erosion.
• Retail versus institutional mix.
• Backorder frequency.
• Contract manufacturing cost.
• Tube and carton economics.
• Reimbursement and wholesaler deductions.
• Ability to maintain uninterrupted supply.

The best commercial case is a disciplined, low-cost product with reliable availability. A differentiated premium product requires measurable benefits in administration, comfort, packaging, or dosing. Marketing language alone will not support durable pricing power.

Key Takeaways

• Gentak is tobramycin 0.3% sterile ophthalmic ointment.
• Its labeled excipients are mineral oil and white petrolatum.
• The lowest-risk generic strategy is a close formulation match using qualified ophthalmic-grade hydrocarbon excipients.
• The core excipient combination is unlikely to create meaningful standalone patent protection.
• Commercial differentiation is more credible through rheology, lower visual blur, tube performance, unit-dose packaging, and supply reliability.
• The key regulatory pathway is generally an ANDA, subject to current FDA requirements for the reference product.
• Current Orange Book listings, ANDA status, patent certifications, and litigation must control any launch or licensing decision.
• The most attractive opportunity is a reliable generic or private-label platform supported by sterile ophthalmic manufacturing capacity.

FAQs About Gentak Excipient Strategy and Commercial Entry

Is Gentak preservative-free?

The labeled ointment formulation uses mineral oil and white petrolatum and does not rely on an aqueous preservative system.[1]

Can a generic Gentak product use different excipients?

A generic may use different inactive ingredients only if FDA requirements for safety, pharmaceutical equivalence, and product performance are satisfied. A direct match generally presents the lower regulatory risk.

Is white petrolatum safe for ophthalmic use?

Pharmaceutical-grade white petrolatum is an established ophthalmic ointment base when manufactured, sterilized or aseptically processed, and packaged under appropriate controls.

Can Gentak be reformulated as an aqueous drop?

An aqueous tobramycin drop would be a different dosage form with different formulation, stability, packaging, sterility, labeling, and regulatory requirements. It would not be a direct ointment equivalent.

Does a new Gentak tube design create patent protection?

A tube or closure design may support intellectual-property protection if it is novel and non-obvious. Its commercial value depends on whether competitors can reproduce the delivery benefit with a different package.

References

1. DailyMed. (n.d.). Gentak: Tobramycin ophthalmic ointment USP, 0.3% prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.